Subepithelial mucinous corneal dystrophy

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics

Subepithelial mucinous corneal dystrophy
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Corneal opacity, vision impairment
Complications	Corneal erosion, vision loss
Onset	Usually in adulthood
Duration	Chronic
Types
Causes	Genetic disorder
Risks
Diagnosis	Slit-lamp examination, genetic testing
Differential diagnosis	Other corneal dystrophies
Prevention
Treatment	Corneal transplantation, phototherapeutic keratectomy
Medication
Prognosis	Variable, may lead to significant vision impairment
Frequency	Rare
Deaths

A rare form of corneal dystrophy

Subepithelial mucinous corneal dystrophy (SMCD) is a rare corneal dystrophy characterized by the accumulation of mucin beneath the corneal epithelium. This condition affects the clarity of the cornea, leading to visual impairment.

Pathophysiology

Subepithelial mucinous corneal dystrophy is primarily caused by the deposition of mucin, a glycoprotein, in the subepithelial region of the cornea. This accumulation disrupts the normal architecture of the cornea, leading to opacification and visual disturbances. The exact mechanism of mucin deposition is not fully understood, but it is believed to involve genetic mutations that affect the production or clearance of mucin in the corneal tissue.

Clinical Presentation

Patients with subepithelial mucinous corneal dystrophy typically present with symptoms of blurred vision, glare, and halos around lights. These symptoms are due to the irregularities in the corneal surface caused by mucin deposits. The condition is usually bilateral, affecting both eyes, and can vary in severity.

Diagnosis

The diagnosis of subepithelial mucinous corneal dystrophy is made through a combination of clinical examination and imaging studies. Slit-lamp examination reveals characteristic subepithelial opacities. Corneal topography and optical coherence tomography (OCT) can be used to assess the extent and depth of the mucin deposits. Genetic testing may also be performed to identify any underlying mutations associated with the condition.

Management

There is currently no cure for subepithelial mucinous corneal dystrophy, and treatment is primarily aimed at managing symptoms and improving vision. Options include:

• Lubricating eye drops: To alleviate discomfort and improve vision by smoothing the corneal surface.
• Contact lenses: Specially designed lenses can help improve vision by providing a smooth refractive surface.
• Corneal transplantation: In severe cases, a corneal transplant may be necessary to restore vision.

Prognosis

The prognosis for individuals with subepithelial mucinous corneal dystrophy varies. Some patients may experience stable vision with minimal intervention, while others may require surgical treatment to maintain visual function. Regular follow-up with an ophthalmologist is essential to monitor the progression of the disease and adjust treatment as needed.

See also

• Corneal dystrophy
• Corneal transplant
• Ophthalmology